Poly(lactic acid)-coated mesoporous silica nanosphere for controlled release of venlafaxine

Journal of Colloid and Interface Science

Volumn 360, Issue 2, 2011, Pages 488-496

  Tang, Jing ^a,b   Slowing, Igor I ^a   Huang, Yulin ^a   Trewyn, Brian G ^a   Hu, Jun ^b   Liu, Honglai ^b   Lin, Victor S Y ^a  

^a IOWA STATE UNIVERSITY   (United States)

^b EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Controlled release; Mesoporous materials; Venlafaxine

Indexed keywords

CONTROLLED RELEASE; FAST DECOMPOSITION; GASTRIC ACID; GASTRIC FLUIDS; INTESTINAL FLUID; MESOPOROUS; MESOPOROUS SILICA; MODEL-BASED OPC; POLY(LACTIC ACID); RELEASE PROCESS; RELEASE RATE; VENLAFAXINE; WEIBULL MODELS;

BODY FLUIDS; HYDROCHLORIC ACID; LACTIC ACID; NANOSPHERES; SILICA;

MESOPOROUS MATERIALS;

PEPSIN A; POLYLACTIC ACID; SILICON DIOXIDE; VENLAFAXINE;

ARTICLE; COMPOSITE MATERIAL; CONTROLLED DRUG RELEASE; DECOMPOSITION; HUMAN; INTESTINE FLUID; PRIORITY JOURNAL; STOMACH ACID; STOMACH JUICE;

COATED MATERIALS, BIOCOMPATIBLE; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; LACTIC ACID; MOLECULAR STRUCTURE; NANOPARTICLES; PARTICLE SIZE; POLYMERS; POROSITY; SILICON DIOXIDE; SURFACE PROPERTIES;

EID: 79958865914     PISSN: 00219797     EISSN: 10957103     Source Type: Journal    
DOI: 10.1016/j.jcis.2011.05.027     Document Type: Article

References (43)

1. Keller M.B. J. Clin. Psychiatry 1999, 60(Suppl. 17):41.
2. Broquet K.E. South Med. J. 1999, 92:846.
3. R. Keltjens, F. Picha, E. Cucala, United States Patent Application 20030191347.
4. Wellington K., Perry C.M. CNS Drugs 2001, 15:643.
5. EFFEXOR® (Venlafaxine Hydrochloride) Tablets' Label, Wyeth Pharmaceuticals Inc. . http://www.pfizer.com.
6. EFFEXOR XR® (Venlafaxine Hydrochloride) Extended-Release Capsules' Label, Wyeth Pharmaceuticals Inc. . http://www.pfizer.com.
7. Rudolph R.L., Feiger A.D. J. Affect Disord. 1999, 56:171.
8. McPartlin G.M., Reynolds A., Anderson C., Casoy J. Prim. Care Psychiatry 1998, 4:127.
9. Silverstone P.H., Ravindran A. J. Clin. Psychiatry 1999, 60:22.
10. Beck J.S., Vartuli J.C., Roth W.J., Leonowicz M.E., Kresge C.T., Schmitt K.D., Chu C.T.W., Olson D.H., Sheppard E.W. J. Am. Chem. Soc. 1992, 114:10834.
11. Kreage C.T., Leonowicz M.E., Roth W.J., Vartuli J.C., Beck S. Nature 1992, 359:710.
12. Slowing I.I., Vivero-Escoto J.L., Wu C., Lin V.S. Adv. Drug Delivery Rev. 2008, 60:1278.
13. Vallet-Regí M., Rámila A., del Real R.P., Pérez-Pariente J. Chem. Mater. 2001, 13:308.
14. Horcajada P., Rámila A., Pérez-Pariente J., Vallet-Regí M. Microporous Mesoporous Mater. 2004, 68:105.
15. Pasqua L., Testa F., Aiello R., Cundari S., Nagy J.B. Microporous Mesoporous Mater. 2007, 103:166.
16. Xu W., Gao Q., Xu Y., Wu D., Sun Y., Shen W., Deng F. J. Solid State Chem. 2008, 181:2837.
17. Li Y., Shi J., Hua Z., Chen H., Ruan M., Yan D. Nano Lett. 2003, 3:609.
18. Li Y., Shi J., Chen H., Hua Z., Zhang L., Ruan M., Yan J., Yan D. Microporous Mesoporous Mater. 2003, 60:51.
19. Zhu Y., Shi J., Li Y., Chen H., Shen W., Dong X. J. Mater. Res. 2005, 20:54.
20. Lai C., Trewyn B.G., Jeftinija D.M., Jeftinija K., Xu S., Jeftinija S., Lin V.S.-Y. J. Am. Chem. Soc. 2003, 125:4451.
21. Mal N.K., Fujiwara M., Tanaka Yuko Nature 2003, 421:350.
22. Fu Q., Rama Rao G.V., Ward T.L., Lu Y., Lopez G.P. Langmuir 2007, 23:170.
23. Bogaert J., Coszach P. Macromol. Symp. 2000, 153:287.
24. Vert M. Macromol. Symp. 2000, 153:333.
25. Jain R.A. Biomaterials 2000, 21:2475.
26. Drumright R.E., Gruber P.R., Henton D.E. Adv. Mater. 2000, 12:1841.
27. Kricheldorf H.R. Chemosphere 2001, 43:49.
28. Radu D.R., Lai C., Wiench J.W., Pruski M., Lin V.S.-Y. J. Am. Chem. Soc. 2004, 126:1640.
29. Manzano M., Aina V., Areán C.O., Balas F., Cauda V., Colilla M., Delgado M.R., Vallet-Regí M. Chem. Eng. J. 2008, 137:30.
30. Crank J. The Mathematics of Diffusion 1975, Oxford University Press, Oxford. second ed.
31. Costa P., Sousa-Lobo J.M. Eur. J. Pharm. Sci. 2001, 13:123.
32. S. Sangeetha, G. Harish, M.K. Samanta, Chitosan-based nanospheres as drug delivery system for cytarabine, Int. J. Pharma Bio Sci. (2010) . http://www.ijpbs.net.
33. Korsmeyer R.W., Gurny R., Doelker E., Buri P., Peppas N.A. Int. J. Pharm. 1983, 15:25.
34. Peppas N.A. Pharm. Acta Helv. 1985, 60:110.
35. Weibull W. J. Appl. Mech. 1951, 18:293.
36. Vudathala G.K., Rogers J.A. J. Pharm. Sci. 1992, 82:282.
37. Antochshuk V., Jaroniec M. Chem. Commun. 1999, 2373.
38. Natural Fibers, Biopolymers, and Biocomposites 2005, CRC Press, Taylor and Francis Group, Boca Raton, FL. A.K. Mohanty, M. Misra, L.T. Drzal (Eds.).
39. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Guidance for Industry, Waiver of In vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, 2000. . http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070246.pdf.
40. Kruk M., Jaroniec M. Chem. Mater. 2001, 13:3169.
41. Asafu-Adjaye E.B., Faustino P.J., Tawakkul M.A., Anderson L.W., Yu L.X., Kwon H., Volpe D.A. J. Pharm. Biomed. Anal. 2007, 43:1854.
42. Zhang X., Wyss U.P., Pichora D., Goosen M.F.A. J. Bioact. Compat. Polym. 1994, 9:80.
43. Patel H.A., Shaha S., Shah D.O., Joshi P.A. Appl. Clay Sci. 2011, 51:126.